Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years

Cancer

Volumn 113, Issue 7, 2008, Pages 1933-1952

  Kantarjian, Hagop ^a   O'Brien, Susan ^a   Cortes, Jorge ^a   Wierda, William ^a   Faderl, Stefan ^a   Garcia Manero, Guillermo ^a   Issa, Jean Pierre ^a   Estey, Elihu ^a   Keating, Michael ^a   Freireich, Emil J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Acute leukemia; Chronic leukemia myelodysplastic syndrome; Prognosis; Survival; Treatment era

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ADENOSINE DERIVATIVE; ANTHRACYCLINE DERIVATIVE; ARSENIC TRIOXIDE; ASPARAGINASE; AZACITIDINE; CHLORODEOXYADENOSINE; CLADRIBINE; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; IMATINIB; MERCAPTOPURINE; METHOTREXATE; NELARABINE; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; RETINOIC ACID; STEROID; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; EPIGENETICS; HAIRY CELL LEUKEMIA; HUMAN; LEUKEMIA; LEUKOCYTOSIS; LEUKOCYTOSIS SYNDROME; LOW DRUG DOSE; MYELODYSPLASTIC SYNDROME; PATHOPHYSIOLOGY; PLEURA EFFUSION; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; REVIEW; SURVIVAL RATE; SURVIVAL TIME;

HUMANS; LEUKEMIA; LEUKEMIA, HAIRY CELL; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 54049126614     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23655     Document Type: Review

References (227)

1. Freireich EJ, Bodey G, Harris J, Hart J. First continuous infusion (12) hour Ara-C 14 patients, 6 CRs and 2 PRs. Therapy for acute granulocytic leukemia, Cancer Res. 1967;27:2573-2577.
2. Boiron M, Weil M, Levey D, et al. Daunorubicin in the treatment of acute myeloblastic leukemia. Lancet. 1969;1:330-333.
3. Ravandi F, Burnett AK, Agura ED, Kantarjian H. Progress in the treatment of acute myeloid leukemia. Cancer. 2007;110:1900-1910.
4. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive post remission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994;331:896-903.
5. Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood. 1996;88:2841-2851.
6. Buchner T, Hiddemann W, Wormann B, et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thio-guanine: a randomized trial by the German AML Cooperative Group. Blood. 1999;93:4116-4124.
7. Bishop JF, Matthews JP, Young GA, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood. 1996;87:1710-1717.
8. Bloomfield CD, Lawrence D, Byrd J, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cyto-genetic subtype. Cancer Res. 1998;58:4173-4179.
9. Kern W, Estey EH. High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: review of 3 randomized trials. Cancer. 2006; 107:116-124.
10. Berman E, Heller G, Santorsa J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood. 1991;77:1666-1674.
11. Wiernik PH, Banks PL, Case D, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood. 1992;79:313-319.
12. Vignetti M, De Witte TM, Suciu S, et al. Daunorubicin (DNR) vs mitoxantrone (MTZ) vs idarubicin (IDA) administered during induction and consolidation in acute myelogenous leukemia (AML) followed by autologous or allogeneic stem transplantation (SCT): results of the EORTC-GIMEMA [ASH Annual Meeting Abstracts]. Blood. 2003;102. Abstract 175.
13. Pautas C, Thomas X, Merabet F, et al. Randomized comparison of standard induction with daunorubicin (DNR) for 3 days vs idarubicin (IDA) for 3 or 4 days in AML pts aged 50 to 70 and of maintenance with interleukin 2. Final analysis of the Alfa 9801 Study [ASH Annual Meeting Abstracts]. Blood. 2007;110. Abstract 162.
14. Estey EH, Thall PF, Pierce S, et al. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin ± all-trans retinoic acid ± granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood. 1999;93:2478-2484.
15. Juliusson G, Hoglund M, Karlsson K, et al. Increased remissions from 1 course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study. Br J Haematol. 2003;123:810-818.
16. Bishop JF, Lowenthal RM, Joshua D, et al. Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group. Blood. 1990;75:27-32.
17. Kantarjian H, Beran M, Cortes J, et al. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Cancer. 2006;106:1099-1109.
18. Tallman M, Nabhan C, Feusner J, Rowe J. Acute promy-elocytic leukemia: evolving therapeutic strategies. Blood. 2002;99:759-767.
19. Tallman M, Anderson J, Schiffer C, et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood. 2002;100:4298-4302.
20. Mathews V, George B, Lakshmi K, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006;107:2627-2632.
21. Sanz MA, Martin G, Rayon C, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARa-positive acute promyelocytic leukemia. Blood. 1999;94:3015-3021.
22. Powell BL, Moser B, Stock W, et al. Effect of consolidation with arsenic trioxide (As2O3) on event-free survival (EFS) and overall survival (OS) among patients with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup Protocol C9710. 2007 ASCO Annual Meeting Proceedings [abstract]. J Clin Oncol. 2007;25(18S). Abstract 2.
23. Lo-Coco F, Cimino G, Breccia M, et al. Gemtuzumab ozo-gamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood. 2004;104:1995-1999.
24. Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood. 2006;107:3469-3473.
25. Marcucci G, Mrozek K, Ruppert A, et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol. 2005;23:5705-5717.
26. Byrd J, Ruppert A, Mrozek K, et al. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv (16) (p13q22) or t (16;16) (p13;q22): results from CALGB 8461. J Clin Oncol. 2004;22:1087-1094.
27. Grimwade D, Walker G, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98:1312-1320.
28. Kantarjian H, O'Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome. Cancer. 2006;106:1090-1098.
29. Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutch-inson RM, Clark RE. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98:1302-1311.
30. Menzin J, Lang K, Earle CC, Kerney D, Mallick R. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med. 2002;162:1597-603.
31. Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006;24:3895-3903.
32. Faderl S, Ravandi F, Ferrajoli A, et al. Clofarabine and clo-farabine plus low dose cytarabine (ara-C) as induction acute myeloid leukemia (AML) [ASH Annual Meeting Abstracts]. Blood. 2005;106. Abstract 786.
33. Giles F, Verstovsek S, Faderl S, et al. A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkyl-ating agent, in patients with very high risk relapsed acute myeloid leukemia. Leuk Res. 2006;30:1591-1595.
34. Lubbert M, Ruter B, Claus R, et al. Continued low-dose decitabine (DAC) is an active first-line treatment in all cytogenetic subgroups of older AML patients: results of the FR00331 multicenter phase II study [ASH Annual Meeting Abstracts]. Blood. 2007;110. Abstract 300.
35. Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109:1114-1124.
36. Kantarjian H. Therapy for elderly patients with acute myeloid leukemia: a problem in search of solutions. Cancer. 2007;109:1007-1010.
37. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood. 1998;92:2322-2333.
38. Byrd J, Mrozek K, Dodge R, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325-4336.
39. Slovak M, Kopecky K, Cassileth P, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood. 2000;96:4075-4083.
40. Gilliland D, Griffin J. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100:1532-1542.
41. Kottaridis P, Gale R, Frew M, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood, 2001;98:1752-1759.
42. Smith BD, Levis M, Beran M, et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood. 2004;103:3669-3676.
43. Stone RM, DeAngelo DJ, Klimek V et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood. 2005.105:54-60.
44. Levis M, Smith BD, Beran M, et al. A randomized, open-label study of lestaurtinib (CEP-701), an oral FLT3 inhibitor, administered in sequence with chemotherapy in patients with relapsed AML harboring FLT3 activating mutations: clinical response correlates with successful FLT3 inhibition [abstract]. Blood. 2005;106:121a.
45. Stone RM, Fischer T, Paquette R, et al. Phase IB study of PKC412, an oral FLT3 kinase inhibitor, in sequential and simultaneous combinations with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed patients with AML [abstract]. Blood. 2006;108:50a.
46. Dohner K, Schlenk R, Habdank M, et al; for the AML Study Group (AMLSG). Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood. 2005;106:3740-3746.
47. Schnittger S, Schoch C, Kern W, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood. 2005;106:3733-3739.
48. Dohner K, Tobis K, Ulrich R, et al. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol. 2002;20:3254-3261.
49. Preudhomme C, Sagot C, Boissel N, et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood. 2002;100:2717-2723.
50. Frohling S, Schlenk RF, Stolze I, et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol. 2004;22:624-633.
51. Baldus CD, Thiede C, Soucek S, Bloomfield CD, Thiel E, Ehninger G. BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications. J Clin Oncol. 2006;24:790-797.
52. Bullinger L, Dohner K, Bair E, et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med. 2004;350:1605-1616.
53. Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 2004;350:1617-1628.
54. Burnett AK, Kell WJ, Goldstone AH, et al. The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: preliminary analysis of 1115 patients in the MRC AML 15 trial [abstract]. Blood. 2006;108:8a.
55. Grovdal M, Khan R, Aggerholm A, et al. Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodys-plastic syndromes and acute myeloid leukemia following myelodysplastic syndrome. Clin Cancer Res. 2007;13:7107-7112.
56. Ravandi F, Kantarjian H, Giles F, Cortes J. New agents in acute myeloid leukemia and other myeloid disorders. Cancer. 2004;100:441-454.
57. Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Emato-logiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med. 1995;332:217-223.
58. Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med. 1998; 339:1649-1656.
59. Archimbaud E, Thomas X, Michallet M, et al. Prospective genetically randomized comparison between intensive postinduction chemotherapy and bone marrow transplantation in adults with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2994;12:262-267.
60. Wong R, Giralt SA, Martin T, et al. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood. 2003;102:3052-3059.
61. Pui CH, Evans W. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166-178.
62. Pui C-H, Relling MV Downing JR. Acute lymphoblastic leukemia. N Engl J Med. 2004;350:1535-1548.
63. Kantarjian H, Thomas D, O'Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD), a dose-intensive regimen, in adult acute lympho-cytic leukemia. Cancer. 2004;101:2788-2801.
64. Faded S, Jeha S, Kantarjian H. The biology and therapy of adult acute lymphoblastic leukemia. Cancer. 2003;98:1337-1354.
65. Durrant IJ, Richards SM, Prentice HG, Goldstone AH. The Medical Research Council trials in adult acute lympho-cytic leukemia. Hematol Oncol Clin North Am. 2000;14:1327-1352.
66. Thiebaut A, Vernant JP, Degos L, et al. Adult acute lym-phocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation: a follow-up report of the French Protocol LALA 87. Hematol Oncol Clin North Am. 2000;14:1353-1365.
67. Gokbuget N, Hoelzer D, Arnold R, et al. Treatment of adult ALL according to protocols of the German Multicen-ter study group for adult ALL (GMALL). Hematol Oncol Clin North Am. 2000;14:1307-1325.
68. Larson RA. Recent clinical trials in acute lymphocytic leukemia by the Cancer and Leukemia Group B. Hematol Oncol Clin North Am. 2000;14:1367-1379.
69. Linker CA, Levitt LJ, O'Donnell M, et al. Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report. Blood. 1991;78:2814-2822.
70. Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005;106:3760-3767.
71. Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood. 2003;101:3809-3817.
72. Mitchell CD, Richards SM, Kinsey SE, et al. Benefit of dexamethasone compared with prednisone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL 97 randomized trial. Br J Haematol. 2005;129:734-745.
73. Hallbook H, Simonsson B, Ahlgren T, et al. High-dose cytarabine in upfront therapy for adult patients with acute lymphoblastic leukaemia. Br J Haematol. 2002;118:748-754.
74. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-0. Blood. 2001;97:1211-1218.
75. Nachman JB, Sather HN, Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998;338:1663-1671.
76. Pession A, Valsecchi MG, Masera G, et al. Long-term results of a randomized trial on extended use of high dose of L-asparaginase for standard risk childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23:7161-7167.
77. Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. Blood. 2000;95:3310-3322.
78. Toyoda Y, Manabe A, Tsuchida M, et al. Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood. J Clin Oncol. 2000;18:1508-1516.
79. Pui C-H. Toward optimal central nervous system-directed treatment in childhood acute lymphoblastic leukemia. J Clin Oncol. 2003;21:179-181.
80. Cortes J, O'Brien SM, Pierce S, et al. The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood. 1995;86:2091-2097.
81. Mancini M, Scappaticci D, Cimino G, et al. A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. Blood. 2005;105:3434-34415.
82. Armstrong SA, Look AT. Molecular genetics of acute lymphoblastic leukemia. J Clin Oncol. 2005;23:6306-6315.
83. Gleissner B, Gokbuget N, Bartram CR, et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood. 2002; 99:1536-1543.
84. Stock W, Sather H, Dodge RK, et al. Outcome of adolescents and young adults with ALL: a comparison of Children's Cancer Group (CCG) and Cancer and Leukemia Group B (CALGB) regimens [abstract]. Blood. 2000;96:467a.
85. Boissel N, Auclerc MF, Lheritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003;21:774-780.
86. de Bont JM, Holt B, Dekker AW, et al. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia. 2004;18:2032-2035.
87. Hallook H, Gustafsson G, Smedmyr B, Soderhall S, Hey-man M; for the Swedish Adult Lymphocytic Leukemia Group, Swedish Childhood Leukemia Group. Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol. Cancer. 2006;107:1551-1561.
88. DeAngelo D, Dahlberg S, Silverman L, et al. A multicenter phase II study using a dose intensified pediatric regimen in adults with untreated acute lymphoblastic leukemia [ASH Annual Meeting Abstracts]. Blood. 2007; 110. Abstract 587.
89. Haiat S, Vekhoff A, Marzac C, et al. Improved outcome of adult acute lymphoblastic leukemia treated with a pediatric protocol: results of a pilot study [ASH Annual Meeting Abstracts]. Blood. 2007;110. Abstract 2822.
90. Huguet F, Raffoux E, Thomas X, et al. Towards a pediatric approach in adults with acute lymphoblastic leukemia (ALL): the GRAALL-2003 Study [ASH Annual Meeting Abstracts]. Blood. 2006;108. Abstract 147.
91. Zhang M, Hoelzer D, Horowitz M, et al. Long-term follow-up of adults with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation. Ann Intern Med. 1995;123:428-431.
92. Attal M, Blaise D, Marit G, et al. Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. BGMT Group. Blood. 1995;86:1619-1628.
93. Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lyphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogenic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008;111:1827-1833.
94. Patte C, Auperin A, Michon J, et al. The Societe Francaise d'Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood. 2001;97:3370-3379.
95. Thomas DA, Faderl S, O'Brien S, et al. Chemoimmu-notherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006;106:1569-1580.
96. Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004; 103:4396-4407.
97. de Labarthe A, Rousselot P, Huguet-Rigal F, et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood. 2006;109:1408-1413.
98. Yanada M, Takeuchi J, Sugiura I, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol. 2006;24:460-466.
99. Fielding A, Richards S, Lazarus H, et al. Does imatinib change the outcome in Philadelphia chromosome positive acute lymphoblastic leukaemia in adults? Data from the UK ALL XII/ECOG2993 study [ASH Annual Meeting Abstracts]. Blood. 2007; 110. Abstract 8.
100. Thomas D, O'Brien S, Cortes J, et al. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood. 2004;104:1624-1630.
101. Kurtzberg J, Ernst TJ, Keating MJ, et al. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol. 2005;23:3396-3403.
102. Berg SL, Blaney SM, Devidas M, et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol. 2005;23:3376-3382.
103. Wetzler M, Dodge RK, Mrozek K, et al. Prospective karyo-type analysis in adult acute lymphoblastic leukemia: the Cancer and Leukemia Group B experience. Blood. 1999; 93:3983-3993.
104. Moorman AV, Harrison CJ, Buck GA, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UK ALL XII/Eastern Cooperative Oncology Group (ECOG) 2993 Trial. Blood. 2007;109:3189-3197.
105. Holleman A, Cheok MH, den Boer ML, et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med. 2004;351:533-542.
106. Lugthart S, Cheok MH, den Boer ML, et al. Identification of genes associated with chemotherapy cross resistance and treatment response in childhood acute lymphoblastic leukemia. Cancer Cell. 2005;7:375-386.
107. Yeoh EJ, Ross ME, Shurtleff SA, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell. 2002;1:133-143.
108. Thomas DA, Cortes J, O'Brien S, et al. Update of the modified hyper-CVAD regimen with or without rituximab in newly diagnosed adult acute lymphocytic leukemia (ALL) [abstract]. Blood. 2005;106:521a. Abstract 1831.
109. Ortmann O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood. 2007;110:2309-2315.
110. Faderl S, Gandhi V, Keating MI, leha S, Plunkett W, Kan-tarjian H. The role of clofarabine in hematologic and solid malignancies-development of a next-generation nucleo-side analog. Cancer. 2005;103:1985-1995.
111. Thomas DA, Sards AH, Cortes I, et al. Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. Cancer. 2006;106:120-127.
112. Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 2002;99:1986-1994.
113. Douer D, Yampolsky H, Cohen LI, et al. Pharmacody-namics and safety of intravenous pegasparginase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood. 2007;109:2744-2750.
114. Jabbour E, O'Brien S, Kantarjian H, et al. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood. 2007;109:3214-3218.
115. Tibes R, Keating MJ, Ferrajoli A, et al. Activity of alemtu-zumab in patients with CD52-positive acute leukemia. Cancer. 2006;106:2645-2651.
116. Strauss SI, Morschhauser F, Rech I, et al. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol. 2006;24:3880-3886.
117. labbour E, Cortes I, Giles F, O'Brien S, Kantarjian H. Current and emerging treatment options in chronic myeloid leukemia. Cancer. 2007;109:2171-2181.
118. Goldman J, Melo J. Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Engl J Med. 2003;349:1451-1464.
119. Kantarjian H, Smith TL, O'Brien S, Beran M, Pierce S, Tal-paz M; and the Leukemia Service. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-a. Ann Intern Med. 1995;122:254-261.
120. [No authors listed] Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group. J Natl Cancer Inst. 1997;89:1616-1620.
121. Kantarjian H, O'Brien S, Cortes I, et al. Complete cytogenetic and molecular responses to interferon-α-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer. 2003;97:1033-1041.
122. Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med. 1999131:207-219.
123. Quintas-Cardama A, Cortes IE. Chronic myeloid leukemia diagnosis and treatment. Mayo Clin Proc. 2006;81:973-988.
124. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004.
125. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;12:908-916.
126. Kantarjian H, Talpaz M, O'Brien S, et al. Imatinib mesy-late for Philadelphia-chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-a: follow-up results. Clin Can Res. 2002;8:2177-2187.
127. Kantarjian H, Talpaz M, O'Brien S, et al. Survival benefit with imatinib mesylate versus interferon-α-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood. 2006; 108:1835-1840.
128. Roy L, Guilhot J, Krahnke T, et al. Survival advantage from imatinib compared with the combination interferon-α plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood. 2006;108:1478-1484.
129. Hochhaus A, Druker BJ, Larson R, O'Brien SG, Gathmann I, Guilhot F. IRIS 6-year follow-up: sustained survival and declining annual rate of transformation in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [ASH Annual Meeting Abstracts]. Blood. 2007;110. Abstract 25.
130. Atallah E, Durand IB, Kantarjian H, Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood. 2007;110:1233-1237.
131. Kantarjian HM, Talpaz M, O'Brien S, et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood. 2003;101:473-475.
132. Marin D, Goldman JM, Olavarria E, Apperley IF. Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses. Blood. 2003;102:2702-2703.
133. Cortes I, Talpaz M, O'Brien S, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res. 2005;11:3425-3432.
134. Branford S, Seymour J, Grigg A, et al. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res. 2007;13:7080-7085.
135. Kantarjian H, Talpaz M, O'Brien S, et al. High dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood. 2004;103:2873-2878.
136. Hughes TP, Brandford S, Matthews J, et al. Trial of higher dose imatinib with selective intensification in newly diagnosed CML patients in chronic phase [abstract]. Blood. 2003;102:31a.
137. Aoki E, Kantarjian H, O'Brien S, et al. High-dose imatinib mesylate treatment in patients (pts) with untreated early chronic phase (CP) chronic myeloid leukemia (CML):2.5-year follow-up [abstract]. Proc Am Soc Clin Oncol. 2006;24. Abstract 6535.
138. Larson R, Druker B, Guilhot F, et al; on behalf of the IRIS Study Group. Correlation of pharmacokinetic data with cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib; an analysis of IRIS study data [ASH Annual Meeting Abstracts). Blood. 2006;108. Abstract 429.
139. Ohnishi K, Nishimura M, Takeuchi J, et al; on behalf of JALSG. Lower dose of imatinib provides outcomes similar to the standard dose imatinib in Japanese patients with early chronic-phase CML: the interim analyses of JALSG CML202 study [ASH Annual Meeting Abstracts]. Blood. 2007;110. Abstract 1044.
140. Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood. 1007;109:58-60.
141. Jabbour E, Kantarjian H, Abruzzo L, et al. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood. 2007;110:2991-2995.
142. Deininger M, Cortes J, Paquette R, et al. The prognosis for patients with
143. Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003;102:276-283.
144. Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002;16:2190-2196.
145. Jabbour E, Kantarjian H, Jones D, et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia. 2006;20:1767-1773.
146. Kantarjian H, O'Brien S, Talpaz M, et al. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer. 2007;109:1556-1560.
147. Lee S, Maziarz R, Kukreja M, et al. Impact of prior therapy with imatinib mesylate on the outcome of hematopoietic cell transplantation (HCT) for chronic myeloid leukemia (CML) [ASH Annual Meeting Abstracts). Blood. 2007;110. Abstract 738.
148. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imati-nib-resistant Philadelphia chromosome-positive leuke-mias. N Engl J Med. 2006;354:2531-2541.
149. Hochhaus A, Kantarjian H, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007;109:303-2309.
150. Guilhot F, Apperley J, Kim DW, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood. 2007;109:4143-50.
151. Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 2007;109:3207-3213.
152. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354:2542-2551.
153. Kantarjian H, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine ki-nase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110:3540-3546.
154. le Coutre P, Ottmann OG, Giles F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated phase chronic myelogenous leukemia. Blood. 2008;111:1834-1839.
155. Cortes J, Bruemmendorf T, Kantarjian H, et al. Efficacy and safety of bosutinib (SKI-606) among patients with chronic phase Ph+ chronic myelogenous leukemia (CML) [ASH Annual Meeting Abstracts]. Blood. 2007;110. Abstract 733.
156. Kantarjian H, Cortes J, Coutre P, et al. A phase I study of INNO-406 in patients with advanced Philadelphia (Ph+) chromosome-positive leukemias who are resistant or intolerant to imatinib and second generation tyrosine kinase inhibitors [ASH Annual Meeting Abstracts). Blood. 2007;110. Abstract 469.
157. Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase II trial. Blood. 2007; 109:5143-5150.
158. Quintas-Cardama A, Kantarjian H, O'Brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007;25:3908-3914.
159. Shah NP, Kantarjian HM, Kim D-W, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008;26:3204-3212.
160. Giles F, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman S. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lym-phocytic leukemia with the T315I BCR-ABL mutation. Blood. 2007;109:500-502.
161. Cortes J, Albitar M, Thomas D, et al. Efficacy of the farne-syl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood. 2003; 101:1692-1697.
162. Issa JP, Gharibyan V, Cortes J, et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol. 2005;23:3948-3956.
163. Marin D, Kaeda JS, Andreasson C, et al. Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib. Cancer. 2005;103:1850-1855.
164. Daley GQ, Van Etten RA, Baltimore D, et al. Induction of chronic myelogenous leukemia in mice by the P210BCR/ABL gene of the Philadelphia chromosome. Science. 1990; 247:824-830.
165. Kelliher MA, McLaughlin J, Witte ON, Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with V-ABL and BCR/ABL. Proc Natl Acad Sci USA. 1990;87:6649-6653.
166. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine ki-nase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108:28-37.
167. Kantarjian H, Schiffer C, Jones D, Cortes J. Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood. 2008;111:1774-1780.
168. Keating MJ, O'Brien S, Lerner S, et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood. 1998;92:1165-1171.
169. Leporrier M, Chevret S, Cazin B, et al; French Cooperative Group on Chronic Lymphocytic Leukemia. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood. 2001;98:2319-2325.
170. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343:1750-1757.
171. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomized controlled trial. Lancet. 2007;370:230-239.
172. Johnson S, Smith AG, Loffler H, et al. Multicentre prospective randomized trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet. 1996;347:1432-1438.
173. O'Brien S, Kantarjian H, Cortes J, et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol. 2001;19:1414-1420.
174. Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006;107:885-891.
175. Flinn IW, Neuberg DS, Grever MR, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol. 2007;25:793-798.
176. Alas S, Emmanouilides C, Bonavida B. Inhibition of inter-leukin 10 by rituximab results in down-regulation of BCL-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res. 2001;7:709-723.
177. Di Gaetano N, Xiao Y, Erba E, et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol. 2001;114:800-809.
178. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4079-4088.
179. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003;101:6-14.
180. Khouri IF, Lee MS, Saliba RM, et al. Nonablative allo-geneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol. 2004;32:28-35.
181. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alem-tuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99:3554-3561.
182. Chanan-Khan A, Miller KC, Musial L, Lawrence D, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol. 2006;24:5343-5349.
183. Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4070-4078.
184. Wierda WG, O'Brien S, Wang X, et al. Prognostic nomo-gram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood. 2007;109:4679-4685.
185. Damie RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD 38 expression as novel progmostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840-1847.
186. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848-1854.
187. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348:1764-1775.
188. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004;351:893-901.
189. Dohner H. Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910-1916.
190. Dohner H, Fischer K, Bentz M, et al. p53 Gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood. 1995;85:1580-1589.
191. Saven A, Piro LD. Treatment of hairy cell leukemia. Blood. 1992;79:1111-1120.
192. Flinn IW, Kopecky KJ, Foucar MK, et al. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pen-tostastin. Blood. 2000;96:2981-2986.
193. Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol. 2003;21:891-896.
194. Grever M, Kopecky K, Foucar MK, et al. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol. 1995;13:974-982.
195. Ravandi F, Jorgensen JL, O'Brien SM, et al. Eradication of minimal residual disease in hairy cell leukemia. Blood. 2006;107:4658-4662.
196. Faderl S, Kantarjian H. Myelodysplastlc syndromes. In: DeVita V, Hellman S, Rosenberg S, eds. Cancer Principles and Practice of Oncology, 7th ed. Lippincott Williams & Wilkins, Philadelphia, Pa; 2005:2144-2154.
197. Faderl S, Kantarjian H. Novel therapies for myelodysplas-tic syndromes. Cancer. 2004;101:226-241.
198. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Heamatol. 1982;51:189-199.
199. Harris NJ, Jaffe ES, Diebold J, et al. World Health Organization lymphoid tissues: report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1977. J Clin Oncol. 1999;17:3835-3849.
200. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088.
201. Malcovati L, Delia Porta M, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision-making. J Clin Oncol. 2005;23:7594-7603.
202. Estey E, Keating M, Pierce S, et al. Application of the international scoring system for myelodysplasia to M. D. Anderson patients. Blood. 1997;90:2843-2844.
203. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002;20:2429-2440.
204. Kantarjian H, Issa J-P, Rosenfeld CS, et al. Decitabine improves patient outcome in myelodysplastic syndrome. Cancer. 2006;106:1794-1803.
205. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic my-elomonocytic leukemia. Blood. 2007;109:52-57.
206. Kantarjian H, O'Brien S, Huang X, et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome. Cancer. 2007;109:1133-1137.
207. Kantarjian H, O'Brien S, Shan J, et al. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer. 2007;109:265-273.
208. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:1456-1465.
209. Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008;111:86-93.
210. Jadersten M, Montgomery SM, Dybedal I, et al. Long-term outcome of treatment of anemia in MDS with erythro-poietin and G-CSF. Blood. 2005;106:803-811.
211. Jadersten M, Malcovati L, Dybedal I, et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol. 2008;26:3607-3613.
212. Urn Z, Killick S, Germing U, et al. Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia. 2007;21:1436-1441.
213. Takatoku M, Uchiyama T, Okamoto S, et al. Retrospective survey of Japanese patients with transfusion-dependent myelodysplastic syndromes and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality [abstract]. Blood. 2006;108:781a. Abstract 2656.
214. Leitch HA, Goodman TA, Wong KK, et al. Improved survival in patients with myelodysplastic syndrome (MDS) receiving iron chelation therapy [abstract]. Blood. 2006; 108:78a. Abstract 249.
215. Rose C, Brechignac S, Vassilief D, et al. Positive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients, a prospective analysis by the GFM [abstract]. Blood. 2007;110:78a. Abstract 249.
216. Lyons R, Cosgriff T, Modi S, et al. Results of the initial treatment phase of a study of three alternative dosing schedules of azacitidine (Vidaza®) in patients with myelodysplastic syndromes (MDS) [abstract]. Blood. 2007;110:246a. Abstract 819.
217. Fenaux P Mufti G, Santini V, et al. Azacitidine (AZA) treatment prolongs overall survival (OS) in higher-risk MDS patients compared with conventional cure regimens (CCR); results of the AZA-001 phase HI study [abstract]. Blood. 2007;110:245a. Abstract 817.
218. Rossetti J, Falke E, Shadduck R, et al. G-CSF increases hematological response among patients with myelodysplasia treated with azacitidine [abstract]. Blood. 2006;108:292b. Abstract 4868.
219. Holsinger A, Ramakrishnan A, Storer B, et al. Therapy of myelodysplastic syndrome (MDS) with azacitidine given in combination with etanercept: a phase II study [abstract]. Blood. 2007;110:420a. Abstract 1452.
220. Beran M, Shen Y, Kantarjian H, et al. Chemotherapy in high-risk myelodysplastic syndrome-Covariate-adjusted comparison of five regimens. Cancer. 2001;92:1999-2015.
221. Sierra J, Perez WS, Rozman C, et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood. 2002;100:1997-2004.
222. Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104:579-585.
223. Haase D, Estey E, Steidl C, et al. Multivariate evaluation of the prognostic and therapeutic relevance of cytogenet-ics in a merged European-American cohort of 3860 patients with MDS [abstract]. Blood. 2007;110:77a. Abstract 247.
224. - syndrome gene by RNA interference screen. Nature. 2008;451:335.
225. Faderl S, Garcia-Manero G, Gandhi V, et al. Results of an exploratory study of oral (po) and intravenous (iv) clofara-bine in patients with myelodysplastic syndrome [abstract]. Blood. 2007;110:421a. Abstract 1455.
226. Vey N, Bosly A, Guerci A, et al. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study. J Clin Oncol. 2006;24:2465-2472.
227. Kantarjian H, Fenaux P, Sekeres MA, et al. Phase 1/2 study of AMG 531 in thrombocytopenic patients (pts) with low-risk myelodysplastic syndrome (MDS): update including extended treatment [ASH Annual Meeting Abstracts]. Blood. 2007;110. Abstract 250.